BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019;14:e0212989. [PMID: 30807613 DOI: 10.1371/journal.pone.0212989] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 2020;20:205-13. [DOI: 10.1080/14712598.2020.1699529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Ye BD, Cheon JH, Song KH, Kim JS, Kim YH, Yoon H, Lee KM, Kang SB, Jang BI, Park JJ, Kim TO, Lee DW, Foo CY, Shin JE, Park DI. The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study. Therap Adv Gastroenterol 2021;14:17562848211024769. [PMID: 34285716 DOI: 10.1177/17562848211024769] [Reference Citation Analysis]
3 Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res 2021;19:71-82. [PMID: 32877600 DOI: 10.5217/ir.2019.09159] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Reference Citation Analysis]
5 Bhandari R, Ogeyingbo OD, Kareem R, Gyawali M, Venkatesan N, Ahmed R, Botleroo RA, Elshaikh AO. Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review. Cureus 2021;13:e17729. [PMID: 34659943 DOI: 10.7759/cureus.17729] [Reference Citation Analysis]
6 Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ohashi A, Kajikawa G, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis. Intern Med 2020;59:3009-14. [PMID: 32727993 DOI: 10.2169/internalmedicine.5302-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
8 George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V. Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis 2020;26:515-23. [PMID: 31504528 DOI: 10.1093/ibd/izz193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
9 Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res 2021;19:95-105. [PMID: 32635680 DOI: 10.5217/ir.2019.09167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol 2020;18:2179-2191.e6. [PMID: 31945470 DOI: 10.1016/j.cgh.2020.01.008] [Cited by in Crossref: 100] [Cited by in F6Publishing: 75] [Article Influence: 50.0] [Reference Citation Analysis]
11 Ikeuchi A, Kakiuchi T, Ibi A, Matsuo M. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan. Clin J Gastroenterol 2021;14:146-51. [PMID: 33040281 DOI: 10.1007/s12328-020-01260-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Inflamm Bowel Dis 2021:izaa361. [PMID: 33501935 DOI: 10.1093/ibd/izaa361] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
14 Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019;14:e0215491. [PMID: 30973957 DOI: 10.1371/journal.pone.0215491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:711-22. [PMID: 33599181 DOI: 10.1080/17474124.2021.1880319] [Reference Citation Analysis]
16 Miyazaki C, Sakashita T, Jung W, Kato S. Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis. Adv Ther 2021;38:2229-47. [PMID: 33515423 DOI: 10.1007/s12325-020-01615-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Banerjee R, Chuah SW, Hilmi IN, Wu DC, Yang SK, Demuth D, Lindner D, Adsul S. Efficacy and safety of vedolizumab in Crohn's disease in patients from Asian countries in the GEMINI 2 study. Intest Res 2021;19:83-94. [PMID: 33378612 DOI: 10.5217/ir.2019.09160] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
19 Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, Koufopoulou M, Iwakiri R. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics 2020;38:69-84. [PMID: 31552601 DOI: 10.1007/s40273-019-00841-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H. Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. Intest Res 2021;19:53-61. [PMID: 32312035 DOI: 10.5217/ir.2019.09146] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, economic and quality-of-life outcomes. Curr Med Res Opin 2022;:1-40. [PMID: 35608153 DOI: 10.1080/03007995.2022.2081453] [Reference Citation Analysis]
22 Naganuma M, Watanabe K, Motoya S, Ogata H, Matsui T, Suzuki Y, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Watanabe M, Hibi T, Kanai T. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J Gastroenterol Hepatol 2021. [PMID: 34409654 DOI: 10.1111/jgh.15667] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Marafini I, Troncone E, Rocchetti I, Monteleone G. Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2020;11:585732. [PMID: 33551798 DOI: 10.3389/fphar.2020.585732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Norton B, Sullivan A, Senior J, Candela N, Jason M, Weyant K. Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners. The Journal for Nurse Practitioners 2022. [DOI: 10.1016/j.nurpra.2021.12.001] [Reference Citation Analysis]
25 Hernandez Santana YE, Irwin N, Walsh PT. IL-36: a therapeutic target for ulcerative colitis? Expert Opin Ther Targets 2022;:1-6. [PMID: 35634891 DOI: 10.1080/14728222.2022.2084381] [Reference Citation Analysis]
26 Zeng J, Wang Z, Yang X. Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis. Eur J Clin Pharmacol. [DOI: 10.1007/s00228-022-03312-3] [Reference Citation Analysis]
27 Vuyyuru SK, Kedia S, Kalaivani M, Sahu P, Kante B, Kumar P, Ranjan MK, Makharia G, Ananthakrishnan A, Ahuja V. Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. Future Microbiol 2021;16:1215-27. [PMID: 34590904 DOI: 10.2217/fmb-2020-0242] [Reference Citation Analysis]
28 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 45.0] [Reference Citation Analysis]
29 Diel R, Schaberg T, Nienhaus A, Otto-Knapp R, Kneitz C, Krause A, Fabri M, Mrowietz U, Bauer T, Häcker B. Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie 2021;75:293-303. [PMID: 33598901 DOI: 10.1055/a-1294-1580] [Reference Citation Analysis]